Skip to main content
main-content
Erschienen in: Die Innere Medizin 7/2022

19.05.2022 | Antikoagulanzien | CME

Gerinnungsdiagnostik im klinischen Alltag – Teil 2

Überwachung von Antikoagulanzientherapien, neu aufgetretene Thrombozytopenie und Thrombophilie

verfasst von: Dr. med. Michael Metze, Dr. med. Martin Platz, Dr. med. Christian Pfrepper, Prof. Dr. med. Sirak Petros

Erschienen in: Die Innere Medizin | Ausgabe 7/2022

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Während bei einer Vitamin-K-Antagonisten-Therapie die Therapieüberwachung (International Normalized Ratio [INR]) obligat ist, gilt dies für direkte orale Antikoagulanzien (DOAK) oder niedermolekulares Heparin (NMH) nur in ausgewählten klinischen Szenarien. Bei DOAK steht die Bestimmung von Tal- und Spitzenspiegeln des Medikaments im Plasma im Vordergrund, bei NMH die Anti-Xa-Aktivität. Der Zeitpunkt der Probenabnahme in Relation zur Einnahme ist für die Bewertung essenziell. Eine neu aufgetretene Thrombozytopenie im Rahmen stationärer Behandlungen ist häufig. Einordnung der Grunderkrankung, Tag des Auftretens sowie Erfassung medikamentöser Einflüsse und ihrer Dynamik ermöglichen oft die Eingrenzung der Ursache. Die Thrombophilietestung nach venöser Thromboembolie wird aufgrund fehlender therapeutischer Konsequenz zunehmend seltener durchgeführt. Ein Antiphospholipidsyndrom darf aber nicht übersehen werden, da sowohl die Therapiedauer als auch die Wahl des Antikoagulans davon abhängen.
Literatur
1.
Zurück zum Zitat Murray D, Pennell B, Olson J (1999) Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion 39:56–62 PubMedCrossRef Murray D, Pennell B, Olson J (1999) Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding. Transfusion 39:56–62 PubMedCrossRef
2.
Zurück zum Zitat Rottenstreich A, Zacks N, Kleinstern G et al (2018) Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 45:543–549 PubMedCrossRef Rottenstreich A, Zacks N, Kleinstern G et al (2018) Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis 45:543–549 PubMedCrossRef
3.
Zurück zum Zitat Wieland E, Shipkova M (2019) Pharmacokinetic and pharmacodynamic drug monitoring of direct-acting oral anticoagulants: where do we stand? Ther Drug Monit 41:180–191 PubMedCrossRef Wieland E, Shipkova M (2019) Pharmacokinetic and pharmacodynamic drug monitoring of direct-acting oral anticoagulants: where do we stand? Ther Drug Monit 41:180–191 PubMedCrossRef
4.
Zurück zum Zitat Testa S, Legnani C, Tripodi A et al (2016) Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost 14:2194–2201 PubMedCrossRef Testa S, Legnani C, Tripodi A et al (2016) Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost 14:2194–2201 PubMedCrossRef
5.
Zurück zum Zitat Francart SJ, Hawes EM, Deal AM et al (2014) Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 111:1133–1140 PubMedCrossRef Francart SJ, Hawes EM, Deal AM et al (2014) Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 111:1133–1140 PubMedCrossRef
6.
Zurück zum Zitat Gosselin R, Grant RP, Adcock DM (2016) Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol 38:505–513 PubMedCrossRef Gosselin R, Grant RP, Adcock DM (2016) Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol 38:505–513 PubMedCrossRef
7.
Zurück zum Zitat Gosselin RC, Adcock DM, Bates SM et al (2018) International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 118:437–450 PubMedCrossRef Gosselin RC, Adcock DM, Bates SM et al (2018) International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 118:437–450 PubMedCrossRef
8.
9.
Zurück zum Zitat Levy JH, Ageno W, Chan NC et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627 PubMedCrossRef Levy JH, Ageno W, Chan NC et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627 PubMedCrossRef
10.
Zurück zum Zitat Tripodi A, Ageno W, Ciaccio M et al (2018) Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIbioC and SIPmeL. Blood Transfus 16:462–470 PubMedPubMedCentral Tripodi A, Ageno W, Ciaccio M et al (2018) Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIbioC and SIPmeL. Blood Transfus 16:462–470 PubMedPubMedCentral
11.
Zurück zum Zitat Douxfils J, Ageno W, Samama CM et al (2018) Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 16:209–219 PubMedCrossRef Douxfils J, Ageno W, Samama CM et al (2018) Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 16:209–219 PubMedCrossRef
12.
Zurück zum Zitat Brunetti L, Sanchez-Catanese B, Kagan L et al (2016) Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thromb J 14:10 PubMedPubMedCentralCrossRef Brunetti L, Sanchez-Catanese B, Kagan L et al (2016) Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thromb J 14:10 PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387 PubMedCrossRef Samama MM, Contant G, Spiro TE et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387 PubMedCrossRef
14.
Zurück zum Zitat Evrard J, Hardy M, Dogne JM et al (2021) Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. Int J Lab Hematol 43:e48–e51 PubMed Evrard J, Hardy M, Dogne JM et al (2021) Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. Int J Lab Hematol 43:e48–e51 PubMed
15.
Zurück zum Zitat Douxfils J, Dogne JM, Mullier F et al (2013) Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 110:543–549 PubMedCrossRef Douxfils J, Dogne JM, Mullier F et al (2013) Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 110:543–549 PubMedCrossRef
17.
Zurück zum Zitat Lam LH, Silbert JE, Rosenberg RD (1976) The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570–577 PubMedCrossRef Lam LH, Silbert JE, Rosenberg RD (1976) The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 69:570–577 PubMedCrossRef
18.
Zurück zum Zitat Basu D, Gallus A, Hirsh J et al (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287:324–327 PubMedCrossRef Basu D, Gallus A, Hirsh J et al (1972) A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287:324–327 PubMedCrossRef
19.
Zurück zum Zitat Marlar RA, Clement B, Gausman J (2017) Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 43:253–260 PubMed Marlar RA, Clement B, Gausman J (2017) Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost 43:253–260 PubMed
20.
Zurück zum Zitat Mitsuguro M, Okamoto A, Shironouchi Y et al (2015) Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. Int J Hematol 101:119–125 PubMedCrossRef Mitsuguro M, Okamoto A, Shironouchi Y et al (2015) Effects of factor VIII levels on the APTT and anti-Xa activity under a therapeutic dose of heparin. Int J Hematol 101:119–125 PubMedCrossRef
21.
Zurück zum Zitat Ratano D, Alberio L, Delodder F et al (2019) Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thromb Res 175:53–58 PubMedCrossRef Ratano D, Alberio L, Delodder F et al (2019) Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin. Thromb Res 175:53–58 PubMedCrossRef
22.
Zurück zum Zitat Descamps R, Moussa MD, Besnier E et al (2021) Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study. Crit Care 25:127 PubMedPubMedCentralCrossRef Descamps R, Moussa MD, Besnier E et al (2021) Anti-Xa activity and hemorrhagic events under extracorporeal membrane oxygenation (ECMO): a multicenter cohort study. Crit Care 25:127 PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Guervil DJ, Rosenberg AF, Winterstein AG et al (2011) Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 45:861–868 PubMedCrossRef Guervil DJ, Rosenberg AF, Winterstein AG et al (2011) Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 45:861–868 PubMedCrossRef
24.
Zurück zum Zitat Raschke RA, Reilly BM, Guidry JR et al (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 119:874–881 PubMedCrossRef Raschke RA, Reilly BM, Guidry JR et al (1993) The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial. Ann Intern Med 119:874–881 PubMedCrossRef
25.
Zurück zum Zitat Hurewitz AN, Khan SU, Groth ML et al (2011) Dosing of unfractionated heparin in obese patients with venous thromboembolism. J Gen Intern Med 26:487–491 PubMedCrossRef Hurewitz AN, Khan SU, Groth ML et al (2011) Dosing of unfractionated heparin in obese patients with venous thromboembolism. J Gen Intern Med 26:487–491 PubMedCrossRef
26.
Zurück zum Zitat Joncas SX, Poirier P, Ardilouze JL et al (2013) Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. Obesity (Silver Spring) 21:1753–1758 CrossRef Joncas SX, Poirier P, Ardilouze JL et al (2013) Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. Obesity (Silver Spring) 21:1753–1758 CrossRef
27.
Zurück zum Zitat Gerlach AT, Folino J, Morris BN et al (2013) Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients. Int J Crit Illn Inj Sci 3:195–199 PubMedPubMedCentralCrossRef Gerlach AT, Folino J, Morris BN et al (2013) Comparison of heparin dosing based on actual body weight in non-obese, obese and morbidly obese critically ill patients. Int J Crit Illn Inj Sci 3:195–199 PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Riney JN, Hollands JM, Smith JR et al (2010) Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother 44:1141–1151 PubMedCrossRef Riney JN, Hollands JM, Smith JR et al (2010) Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients. Ann Pharmacother 44:1141–1151 PubMedCrossRef
29.
Zurück zum Zitat Shin S, Harthan EF (2015) Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. Blood Coagul Fibrinolysis 26:655–660 PubMedCrossRef Shin S, Harthan EF (2015) Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review. Blood Coagul Fibrinolysis 26:655–660 PubMedCrossRef
30.
31.
Zurück zum Zitat Schwarz E, Usteri C, Koller F (1950) Heparin tolerance and heparin hypersensitivity. Acta Haematol 4:148–157 PubMedCrossRef Schwarz E, Usteri C, Koller F (1950) Heparin tolerance and heparin hypersensitivity. Acta Haematol 4:148–157 PubMedCrossRef
32.
Zurück zum Zitat Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S–203S PubMedCrossRef Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:188S–203S PubMedCrossRef
33.
Zurück zum Zitat Levy JH (2004) Heparin resistance and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth 18:129–130 PubMedCrossRef Levy JH (2004) Heparin resistance and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth 18:129–130 PubMedCrossRef
34.
35.
Zurück zum Zitat Al Dieri R, Alban S, Beguin S et al (2006) Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4:83–89 PubMedCrossRef Al Dieri R, Alban S, Beguin S et al (2006) Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost 4:83–89 PubMedCrossRef
36.
Zurück zum Zitat Kroon C, ten Hove WR, de Boer A et al (1992) Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86:1370–1375 PubMedCrossRef Kroon C, ten Hove WR, de Boer A et al (1992) Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86:1370–1375 PubMedCrossRef
37.
Zurück zum Zitat Witt DM, Nieuwlaat R, Clark NP et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2:3257–3291 PubMedPubMedCentralCrossRef Witt DM, Nieuwlaat R, Clark NP et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2:3257–3291 PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Fachinformation Mono-Embolex Stand 2021 Fachinformation Mono-Embolex Stand 2021
39.
40.
41.
42.
43.
Zurück zum Zitat Barrett JS, Hainer JW, Kornhauser DM et al (2001) Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. Thromb Res 101:243–254 PubMedCrossRef Barrett JS, Hainer JW, Kornhauser DM et al (2001) Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers. Thromb Res 101:243–254 PubMedCrossRef
44.
Zurück zum Zitat Atiq F, van den Bemt PM, Leebeek FW et al (2015) A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. Eur J Clin Pharmacol 71:921–929 PubMedPubMedCentralCrossRef Atiq F, van den Bemt PM, Leebeek FW et al (2015) A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency. Eur J Clin Pharmacol 71:921–929 PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Cuker A, Arepally GM, Chong BH et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:3360–3392 PubMedPubMedCentralCrossRef Cuker A, Arepally GM, Chong BH et al (2018) American society of hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv 2:3360–3392 PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Farge D, Frere C, Connors JM et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20:e566–e581 PubMedCrossRef Farge D, Frere C, Connors JM et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20:e566–e581 PubMedCrossRef
47.
Zurück zum Zitat Yukizawa Y, Inaba Y, Watanabe S et al (2012) Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty. J Thromb Thrombolysis 34:526–532 PubMedCrossRef Yukizawa Y, Inaba Y, Watanabe S et al (2012) Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty. J Thromb Thrombolysis 34:526–532 PubMedCrossRef
48.
49.
51.
Zurück zum Zitat Kohli R, Chaturvedi S (2019) Epidemiology and clinical manifestations of immune thrombocytopenia. Hamostaseologie 39:238–249 PubMedCrossRef Kohli R, Chaturvedi S (2019) Epidemiology and clinical manifestations of immune thrombocytopenia. Hamostaseologie 39:238–249 PubMedCrossRef
52.
Zurück zum Zitat Greinacher A, Selleng K (2010) Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010:135–143 PubMedCrossRef Greinacher A, Selleng K (2010) Thrombocytopenia in the intensive care unit patient. Hematology Am Soc Hematol Educ Program 2010:135–143 PubMedCrossRef
53.
Zurück zum Zitat Warkentin TE (2007) Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med 356:891–893 PubMedCrossRef Warkentin TE (2007) Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med 356:891–893 PubMedCrossRef
54.
Zurück zum Zitat Cuker A, Gimotty PA, Crowther MA et al (2012) Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 120:4160–4167 PubMedPubMedCentralCrossRef Cuker A, Gimotty PA, Crowther MA et al (2012) Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 120:4160–4167 PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Kearon C, Parpia S, Spencer FA et al (2018) Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood 131:2151–2160 PubMedPubMedCentralCrossRef Kearon C, Parpia S, Spencer FA et al (2018) Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood 131:2151–2160 PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Lijfering WM, Brouwer JL, Veeger NJ et al (2009) Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 113:5314–5322 PubMedCrossRef Lijfering WM, Brouwer JL, Veeger NJ et al (2009) Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 113:5314–5322 PubMedCrossRef
57.
Zurück zum Zitat Baglin T, Gray E, Greaves M et al (2010) Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 149:209–220 PubMedCrossRef Baglin T, Gray E, Greaves M et al (2010) Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 149:209–220 PubMedCrossRef
58.
Zurück zum Zitat Connors JM (2017) Thrombophilia testing and venous thrombosis. N Engl J Med 377:1177–1187 PubMedCrossRef Connors JM (2017) Thrombophilia testing and venous thrombosis. N Engl J Med 377:1177–1187 PubMedCrossRef
59.
Zurück zum Zitat Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41:543–603 PubMedCrossRef Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41:543–603 PubMedCrossRef
60.
Zurück zum Zitat Coppens M, Reijnders JH, Middeldorp S et al (2008) Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 6:1474–1477 PubMedCrossRef Coppens M, Reijnders JH, Middeldorp S et al (2008) Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 6:1474–1477 PubMedCrossRef
61.
Zurück zum Zitat Couturaud F, Leroyer C, Tromeur C et al (2014) Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood 124:2124–2130 PubMedPubMedCentralCrossRef Couturaud F, Leroyer C, Tromeur C et al (2014) Factors that predict thrombosis in relatives of patients with venous thromboembolism. Blood 124:2124–2130 PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Stevens SM, Woller SC, Bauer KA et al (2016) Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 41:154–164 PubMedPubMedCentralCrossRef Stevens SM, Woller SC, Bauer KA et al (2016) Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis 41:154–164 PubMedPubMedCentralCrossRef
63.
Zurück zum Zitat Prandoni P, Noventa F, Ghirarduzzi A et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92:199–205 PubMedCrossRef Prandoni P, Noventa F, Ghirarduzzi A et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92:199–205 PubMedCrossRef
64.
Zurück zum Zitat Siriez R, Dogne JM, Gosselin R et al (2021) Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 43:7–20 PubMedCrossRef Siriez R, Dogne JM, Gosselin R et al (2021) Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 43:7–20 PubMedCrossRef
65.
Zurück zum Zitat Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378:2010–2021 PubMedCrossRef Garcia D, Erkan D (2018) Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 378:2010–2021 PubMedCrossRef
66.
Zurück zum Zitat Pengo V, Denas G, Zoppellaro G et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365–1371 PubMedCrossRef Pengo V, Denas G, Zoppellaro G et al (2018) Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 132:1365–1371 PubMedCrossRef
Metadaten
Titel
Gerinnungsdiagnostik im klinischen Alltag – Teil 2
Überwachung von Antikoagulanzientherapien, neu aufgetretene Thrombozytopenie und Thrombophilie
verfasst von
Dr. med. Michael Metze
Dr. med. Martin Platz
Dr. med. Christian Pfrepper
Prof. Dr. med. Sirak Petros
Publikationsdatum
19.05.2022